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ABSTRACT
Objectives Extra-articular manifestations (EAMs) are
important systemic features of axial spondyloarthritis (axSpA),
which may influence the choice of tumour necrosis factor-
inhibitor (TNFi). We examined the cumulative incidence and
predictors of EAMs and the influence of these on first TNFi
choice in a ‘real-world’ cohort of patients with axSpA.
Methods Clinical and patient-reported outcomes of
2420 patients with axSpA from 83 centres were collected
by the British Society for Rheumatology Biologics
Register in Ankylosing Spondylitis. Lifestyle factors for
EAMs (acute anterior uveitis (AAU), inflammatory bowel
diseases (IBD), psoriasis) were compared with those
without EAMs. Also, the association between
pretreatment EAMs and choice of first TNFi (adalimumab,
etanercept, certolizumab) was analysed.
Results AAU was directly associated with human
leukocyte antigen (HLA)-B27 (incidence rate ratio (IRR) 1.95,
95% CI 1.40 to 2.73) and inversely associated with ever-
smoking (IRR=0.71, 95% CI 0.55 to 0.92). For both psoriasis
and IBD, there was an inverse relationship with HLA-B27
(IRR 0.54, 95% CI 0.36 to 0.79 and IRR 0.63, 95% CI 0.43 to
0.91, respectively). A diagnosis of either AAU (OR 3.79, 95%
CI 2.11 to 6.80) or IBD (OR 5.50, 95% CI 2.09 to 14.46) was
associated with preference for adalimumab versus others.
In contrast, a diagnosis of either AAU (OR 0.14, 95% CI 0.06
to 0.33) or IBD (OR 0.17, 95% CI 0.05 to 0.57) was
associated with less preference for etanercept over other
TNFi.
Conclusion The higher occurrence of AAU and lower
occurrence of psoriasis and IBD in HLA-B27-positive
patients with axSpA are consistent with current
pathophysiology. Patients with previous AAU and IBD are
more likely to be prescribed adalimumab and less likely to
receive etanercept, consistent with the superior efficacy of
monoclonal TNFi for these indications. Future work will
determine whether EAMs influence TNFi survival, or
effectiveness, and whether this varies between agents.
INTRODUCTION
Extra-articular manifestations (EAMs) are com-
mon and important systemic features of axial
spondyloarthritis (axSpA), the most common
being acute anterior uveitis (AAU), inflamma-
tory bowel disease (IBD) and psoriasis. It has
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Key messages
What is already known about this subject
► Extra-articular manifestations (EAMs) are common
and important features of axial spondyloarthritis
(axSpA).
► The efficacy of TNF-inhibitors (TNFis) for EAMs is
variable due to their different modes of action.
What this study add
► This study demonstrates that one in three patients
with axSpA have at least one EAM; however, 84%
have a single EAM, suggesting that there are
unrelated pathogenic mechanisms.
► Acute anterior uveitis is significantly associated with
HLA-B27; however, patients with psoriasis and
inflammatory bowel disease have lower rates of
HLA-B27 positivity than the overall cohort.
► The presence of EAMs does not increase the
likelihood of patients being started on a TNFi;
however, EAMs do influence TNFi choice.
How might this impact on clinical practice
► This study raises awareness of potential impact of
EAMs on prescribing patterns in axSpA. Longitudinal
analysis will determine whether EAMs influence TNFi
survival and whether or not individual TNFi protect
patients from incident or flares of existing EAMs.
Spondyloarthritis
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previously been estimated that the pooled prevalence of
AAU, psoriasis and IBD in axSpA are 16–23%, 10–11%
and 4–6%, respectively.1 The prevalence of EAMs is broadly
similar in ankylosing spondylitis (AS; also called radio-
graphic axSpA) and non-radiographic axSpA (nr-axSpA),
except for AAU prevalence that is higher in AS than nr-
axSpA.1 EAMs contribute to the disease burden and add
a layer of complexity to the management of axSpA.2 3
National and international recommendations for the
management of axSpA consistently highlight the impor-
tance of considering EAMs when choosing the appropri-
ate tumour necrosis factor inhibitor (TNFi) due to their
different modes of action and efficacy in the context of
individual EAMs.2 4 5 In the UK, Europe and North Amer-
ica, five originator TNFi are currently licensed to treat
axSpA; adalimumab, certolizumab pegol, etanercept,
golimumab and infliximab (AS only). Several TNFi are
also licensed to treat psoriasis (all except golimumab)
and IBD (ulcerative colitis—adalimumab, infliximab
and golimumab; Crohn’s disease—adalimumab and
infliximab (certolizumab in the USA and Switzerland
only)). However, no TNFi are currently licensed to treat
AAU in adults, although adalimumab is licensed to treat
non-infectious intermediate, posterior and panuveitis.6
In a post hoc analysis of randomised controlled trials for
axSpA and other conditions, as well as in many observa-
tional studies, it has been shown that monoclonal TNFi
are efficacious in AAU, with monoclonal antibody TNFi
showing superior efficacy over etanercept.7–9
EAMs therefore have important implications for the use
of TNFi, particularly the soluble fusion protein etaner-
cept, in the management of axSpA. However, it is not
feasible or ethical to randomise patients with axSpA and
specific EAMs to specific treatments in conventional ran-
domised controlled trial settings, so data from real-world
cohorts are required. Specifically, physicians’ beliefs and
knowledge about the efficacy and safety of specific TNFi
for AAU, IBD and psoriasis are likely to influence their
choice of TNFi in patients with axSpA. The purpose of
this study is to examine the cumulative incidence and
predictors for developing EAMs and their influence on
physicians’ prescribing patterns for the first TNFi in
a ‘real-life’ cohort of patients with axSpA recruited in
the UK.
METHODS
Participants data
The British Society for Rheumatology Biologics Register in
Ankylosing Spondylitis (BSRBR-AS) is a UK-wide prospec-
tive observational cohort study of patients with axSpA
recruited from 83 centres and fulfilling the Assessment of
SpondyloArthritis International Society (ASAS) classifica-
tion criteria.10 The BSRBR-AS study protocol has been
published previously.11 Baseline data were obtained
between December 2012 and June 2017 using
a combination of a targeted medical history, participant
self-completed questionnaires and the participants’
medical records. The presence or absence of EAMs (ever
diagnosis), defined as physician-verified diagnosis of AAU,
psoriasis and IBD, were specifically recorded prior to com-
mencing biological therapy. Demographic data included
age, disease duration (time between symptom onset to
BSRBRAS baseline visit), bodymass index (BMI), cigarette
smoking status (ever vs never used for this analysis), alco-
hol consumption and educational status. Human leuko-
cyte antigen (HLA)-B27 status was determined from either
medical records or analysis of patients’ saliva samples.
In the original data set, there were only a small propor-
tion of missing data (<5%) in variables of interests; there-
fore, we have not applied any imputation methods to our
data set.
Ethical approval was obtained from the National
Research Ethics Service Committee North East—County
Durham and Tees Valley (reference 11/NE/0374), and
signed informed consent was obtained from all
participants.
Statistical analysis
Descriptive statistics were used to compare participant
characteristics according to presence or absence (ever
diagnosis) of AAU, psoriasis and IBD (either Crohn’s
disease or ulcerative colitis), with central tendencies in
groups presented as median and IQR, unless otherwise
stated. Where necessary, the difference between inde-
pendent groups was examined using the Mann-
Whitney U test. Poisson log-linear models were used
to examine the associations between each EAM (AAU,
psoriasis, IBD) and demographic, lifestyle and HLA-
B27 status. In unadjusted models, estimates of inci-
dence rate ratio (IRR) and relevant 95% CI were
calculated with one EAM as response and one factor
as predictor. In adjusted models, all factors (categori-
cal) and covariate (continuous) variables showing sig-
nificant association (p<0.05) with the response in
univariable analysis were entered in the model. In
final models, when AAU was the response, HLA-B27
(reference: negative), university degree (reference:
no) and ever-smoking (reference: never) were factors,
and age (years) and axSpA disease duration (years)
were covariates. In the model for psoriasis, HLA-B27
(reference: negative), university degree (reference:
no) and ever-smoking (reference: never) were factors,
and age (years) and BMI were covariates. In the model
for IBD as response, only HLA-B27 (reference: nega-
tive) was entered as factor, and age (years) and axSpA
disease duration (years) as covariates. For each EAM,
the final models’ type was Poisson log-linear, the max-
imum iterations were 100 and maximum step-halving
was 5. The convergence criteria defined as a change in
parameter estimate of 1e-006 or more.
To examine the associations between EAMs and the
choice of first TNFi, logistic regression models were
used. In univariable analyses, separate models were con-
structed with etanercept versus monoclonal TNFis as
dependent variable, and pretreatment diagnosis of
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AAU, psoriasis and IBD (as Crohn’s disease only, ulcera-
tive colitis only and combined). Other demographic and
lifestyle factors included in the models were age, gender,
axSpA disease duration, BASDAI (Bath Ankylosing Spon-
dylitis Disease Activity Index) score, BASFI (Bath Ankylos-
ing Spondylitis Functional Index) score, HLA-B27 status,
smoking status, education and BMI. Factors with signifi-
cant associations (p<0.05) in univariable models were
entered into the multivariable model, again with choice
of TNFi (etanercept vs monoclonal TNFis) as dependent
variable. Pretreatment diagnosis of AAU, IBD, education
status, BASDAI and BASFI were included in the final
model. The entered method was chosen for the final
multivariable analyses to keep all variable in the model.
Magnitude of associations were presented as ORs and
95% CI.
RESULTS
Baseline data for 2419 participants were available for the
current analysis. Approximately a third of the cohort
(927; 32%) had one or more EAM of interest present
prior to receiving biological therapy; of these 780
(84.1%) had only one EAM, 142 (15.3%) had two EAMs
and 5 (0.5%) participants had all three EAMs. The fre-
quency of AAU, psoriasis and IBD at the baseline visit
were 23.5% (568), 10.9% (264) and 10.2% (247), respec-
tively. The baseline demographic, lifestyle factors and
HLA-B27 status of the whole cohort and those with
EAMs are shown in table 1.
Associations with AAU
AAU was the most common EAM reported in 568
(23.5%) of participants (table 1). In the univariable
analysis, significant positive associations in the AAU
cohort included older age (IRR 1.01, 95% CI 1.01 to
1.021 per year), longer disease duration (IRR 1.02,
95% CI 1.01 to 1.02), HLA-B27 (IRR 1.92, 95% CI
1.42 to 2.61) and university education (1.30, 95% CI
1.08 to 1.57). Conversely, the proportion of patients
who ever-smoked was significantly lower in the AAU
group (IRR 0.77, 95% CI 0.64 to 0.92). Additional
analysis revealed a confounding between education
and ever-smoking, indicating that the higher occur-
rence of AAU in those with university education was
due to lower proportion of ever-smoking in that group
(ever-smoking was 20.9% in those with university
degree compared to 79.1% in those without
a university degree; p<0.001). There was no associa-
tion between AAU and gender, BMI or alcohol
consumption.
In the multivariable analysis (table 2), HLA-B27 was
associated with an increase in the risk of AAU (IRR
1.95, 95% CI 1.40 to 2.73). In contrast, ever-smoking
was associated with reduced risk of AAU (IRR 0.71,
95% CI 0.55 to 0.92). Other parameters including
university education, age and axSpA disease duration
did not demonstrate a significant association with
AAU in this cohort using our predefined cut-offs,
although age and disease duration were assessed
per year so may still have a cumulative effect over
time.
Associations with psoriasis
Psoriasis was reported in 264 (10.9%). In univariable
analysis, significant positive associations with psoriasis
were seen for older age (IRR 1.01, 95% CI 1.01 to
1.02), BMI (IRR 1.03, 95% CI 1.01 to 1.05) and ever-
smoking (IRR 1.30, 95% CI 1.00 to 1.70), while the
participants with axSpA and psoriasis were less likely
to be HLA-B27 positive (IRR 0.50, 95% CI 0.36 to
0.64). Ever-drinking alcohol or having a university
degree were not significantly different in the psoria-
sis group compared to the entire cohort. In the mul-
tivariable analysis (table 2), only HLA-B27 status
remained as independent predictor of psoriasis
(IRR 0.54, 95% CI 0.37 to 0.79). The other para-
meters, including age and BMI, did not demonstrate
a statistically significant association with a diagnosis
of psoriasis in this axSpA cohort.
Table 1 Characteristics of entire cohort and subgroups with extra-articular manifestations
Entire cohort
(n=2419)
With AAU
(n=568, 23.5%)
With psoriasis
(n=264, 10.9%)
With IBD
(n=247, 10.2%)
Gender (male) 68.4% 66.7% 67.4% 65.2%
Age (years), median (IQR) 47.0 (36.0–59.0) 51.0 (41.0–61.0) 51.5 (38–62) 52.0 (40.0–63.0)
AxSpA disease duration (years), median (IQR) 16.0 (7.0–30.0) 22.0 (11.0–34.0) 17.5 (7.0–32.0) 20.0 (8.0–35.0)
BMI (kg/m2), median (IQR) 26.8 (23.9–30.7) 27.3 (24.0–31.0) 27.7 (24.4–31.4) 27.1 (24.0–30.8)
HLA-B27 positive 80.1% 88.7% 66.7% 71.4%
University degree 27.8% 33.5% 27.2% 24.8%
Ever-smoker 56.2% 50.1% 62.7% 59.7%
Ever-drinking alcohol 93.0% 94.2% 94.0% 92.1%
AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BMI, body mass index; HLA, human leukocyte antigen; IBD, inflammatory bowel
disease.
Spondyloarthritis
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Associations with IBD
There were 247 (10.2%) patients with a diagnosis of IBD
(table 1). In the univariable analysis, positive associations
with IBD were older age (IRR 1.02, 95% CI 1.01 to 1.03)
and longer axSpA disease duration (IRR 1.01, 95% CI
1.00 to 1.02). In contrast, HLA-B27 was significantly
lower in the IBD group (IRR 0.65, 95% CI 0.43 to 0.89).
There were no significant associations in this cohort
between a diagnosis of IBD and ever-smoking, ever-
drinking, BMI or education level.
Similar to the findings in participants with psoriasis,
multivariable analysis identified only HLA-B27 status as
an independent negative predictor of a diagnosis of IBD
with an IRR of 0.63 (95% CI 0.43 to 0.91). Other para-
meters including age and axSpA disease duration did not
demonstrate a statistically significant association with IBD
(table 2).
EAMs and choice of biologic
A total of 947 (39.1%) participants received their first
biologic during the course of the observation period.
The TNFi biologics were adalimumab (n=598, 63.1%; all
Humira), etanercept (n=266, 28.1%; consisted of 240
Enbrel and 26 biosimilar Benepali), certolizumab
(n=73, 7.7%) and golimumab (n=9, 1.0%). One partici-
pant (0.1%) treated with the interleukin (IL)-17A inhibi-
tor, secukimumab, was excluded from this analysis.
Overall, the presence of EAMs did not influence the like-
lihood of receiving treatment with TNFi, with 66% of
participants with an EAM receiving TNFi compared with
66.4% without an EAM (p=0.836).
Treatment and choice of biologic in the BSRBR-AS
cohort was at the discretion of the usual treating clinical
physician and unrelated to participation in the study. In
order to determine which demographic factors and dis-
ease measurements were associated with selection of the
soluble fusion protein TNFi, etanercept, compared to the
monoclonal antibody TNFis (adalimumab, certolizumab
or golimumab in this cohort), separate logistic regression
models were developed. Univariable analysis revealed
that baseline BASDAI score (OR 1.15, 95% CI 1.06 to
1.24) and BASFI score (OR 1.11, 95% CI 1.04 to 1.18)
were significantly associated with the choice of etanercept
over monoclonal TNFi. Conversely, having higher educa-
tion (university education and above) was associated with
less use of etanercept over monoclonal TNFi (OR 0.73,
95% CI 0.54 to 0.99). None of other demographic or
lifestyle variables, including age, gender, disease dura-
tion, HLA-B27, smoking and BMI, were associated with
the choice of TNFi.
Considering EAMs in the univariable models, ever diag-
nosis of AAU (as binary yes: no) and number of AAU
episodes in the last 12 months were both significantly
associated with less use of etanercept compared to mono-
clonal TNFi (OR 0.29, 95% CI 0.19 to 0.46 and OR 0.48,
95% CI 0.30 to 0.77, respectively)). Also, patients with
ever diagnosis of IBD in any form (all IBD, Crohn’s dis-
ease alone and ulcerative colitis alone) were less likely to
Table 2 Factors and covariates associated with a diagnosis of specific EAM in patients with axSpA (multivariable models)
Parameter B SE P value
Incidence rate ratio
(IRR) 95% CI for IRR
A. Diagnosis of AUU
(Intercept) −2.370 0.2788 <0.001 0.093 0.054–0.161
HLA-B27 positive (vs negative) 0.669 0.1710 <0.001 1.953 1.396–2.730
University degree (vs lower) 0.165 0.1507 0.273 1.179 0.878–1.585
Ever-smoking (vs never) −0.349 0.1322 0.008 0.706 0.545–0.915
Age (years) 0.009 0.0053 0.093 1.009 0.999–1.019
axSpA disease duration (years) 0.005 0.0050 0.305 1.005 0.995–1.015
B. Diagnosis of Psoriasis
(Intercept) −3.069 0.592 0.000 0.046 0.015–0.148
HLA-B27 positive (vs negative) −0.621 0.197 0.002 0.538 0.365–0.791
University degree (vs lower) 0.326 0.283 0.248 1.386 0.796–2.412
Ever-smoking (vs never) 0.256 0.228 0.262 1.292 0.826–2.020
Age (years) 0.009 0.007 0.173 1.009 0.996–1.022
BMI (kg/m2) 0.022 0.016 0.155 1.023 0.992–1.05
C. Diagnosis of IBD
(Intercept) −2.698 0.3617 <0.001 0.067 0.033–0.137
HLA-B27 positive (vs negative) −0.466 0.1894 0.014 0.627 0.433–0.909
Age (years) 0.012 0.0079 0.128 1.012 0.997–1.028
axSpA disease duration (years) 0.003 0.0078 0.671 1.003 0.988–1.019
AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BMI, body mass index; EAM, extra-articular manifestation; HLA, human leukocyte
antigen; IBD, inflammatory bowel disease.
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receive etanercept over monoclonal TNFi in univariable
models (OR 0.35, 95% CI 0.20 to 0.62). In contrast, ever
diagnosis of psoriasis was not associated with choice of any
particular TNFi (OR 0.74, 95% CI 0.47 to 1.16) (table 3).
In multivariable analysis (table 4), both ever diagnosis
of AAU (OR 0.15, 95%CI 0.08 to 0.29) and ever diagnosis
of IBD (OR 0.30, 95% CI 0.16 to 0.56) remained signifi-
cantly associated with less use of etanercept compared to
monoclonal TNFis. Among other factors, only BASDAI
score had a significant association with the preference of
etanercept over monoclonal TNFi (OR 1.16, 95% CI 1.03
to 1.30).
DISCUSSION
In this large real-world cohort of patients with axSpA, EAMs
are common, with approximately a third of participants
reporting at least one EAM. The occurrence of EAMs in
this cohort is approximately similar to previous published
reports in similar populations.12–14 Interestingly, among
patients who had EAMs, most (84%) of the participants
only had a single EAM, suggesting that while there may be
shared pathogenetic processes between EAMs and axSpA,
there are also likely to be unrelated pathogenic mechan-
isms. This is consistent with the existing and emerging
pathogenetic and treatment response data for these
conditions.15 16
The presence of AAU in this axSpA cohort was signifi-
cantly associated with HLA-B27 status. This is consistent
with previous reports7 17 and offers a potential strategy for
targeted identification of people with AAU in ophthal-
mology clinics who may have underlying axSpA.18–20
Interestingly, participants with IBD and psoriasis had
lower rates of HLA-B27 positivity than the overall cohort
and both had negative associations with HLA-B27 status,
consistent with results froma recent study byVarkas et al.21
This may indicate that people with psoriasis or IBD and
back pain are more likely to be diagnosed with axSpA,
regardless of their HLA-B27 status. Interestingly,
a positive HLA-B27 (plus at least two other SpA features,
which could include psoriasis or IBD) is required to fulfil
the clinical arm of the ASAS classification criteria for
axSpA10; this may suggest that these participants are
more likely to fulfil the imaging arm (HLA-B27 not
required). An alternative explanation could be that clin-
icians rely more on diagnostic likelihood and clinical
acumen rather than rigorously adhering to classification
criteria, which would be appropriate as classification cri-
teria are not intended for diagnostic use in clinical
practice.22 23 Finally, it is also possible that axSpA is
under-diagnosed in patients with dominant IBD or psor-
iasis, particularly those who are HLA-B27 positive.24–27
The current study indicated that smoking is associated
with lower occurrence of AAU but not associated with
psoriasis or IBD. The inverse association between AAU
Table 3 Summary of factors associated with choice of
etanercept over monoclonal antibody TNFis in patients with
axSpA (summary of separate univariable models)
Variable Wald P value OR
95% CI for
OR
Gender (male vs
female)
3.561 0.059 1.351 0.988–1.847
Age (years) 0.842 0.359 0.995 0.984–1.006
Disease duration
(years)
2.062 0.151 0.992 0.980–1.003
BASDAI score 12.226 <0.001 1.146 1.062–1.237
BASFI score 10.393 0.001 1.107 1.041–1.178
HLA-B27
positivity
0.033 0.856 1.038 0.692–1.557
Smoking (current
vs none)
1.525 0.217 1.268 0.870–1.848
Smoking (ex-
smoking vs none)
0.084 0.772 1.054 0.736–1.510
Education
(ordinal)
3.543 0.060 0.893 0.793–1.005
Education
(university degree
vs lower)
4.084 0.043 0.730 0.539–0.991
BMI (kg/m2) 0.365 0.546 0.956 0.826–1.106
AAU (any) 27.943 <0.001 0.294 0.187–0.463
AAU episodes in
last 12 months
9.336 0.002 0.484 0.304–0.771)
IBD (Crohn’s
disease or
ulcerative colitis)
13.081 <0.001 0.354 0.201–0.621
Crohn’s disease 9.457 0.002 0.044 0.006–0.323
Ulcerative colitis 7.456 0.006 0.192 0.056–0.628
Psoriasis 1.707 0.191 0.738 0.468–1.164
AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BASDAI,
Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath
Ankylosing Spondylitis Functional Index; BMI, body mass index;
EAM, extra-articular manifestation; HLA, human leukocyte antigen;
IBD, inflammatory bowel disease; TNFi, tumour necrosis factor-
inhibitor.
Table 4 Summary of factors associated with choice of
etanercept over monoclonal TNFis in patients wth axSpA
(summary of multivariable model)
Variable Wald P value OR
95% CI for
OR
BASDAI score 5.941 0.015 1.158 1.029–1.304
BASFI score 0.315 0.577 1.028 0.932–1.135
Education
(university degree
vs lower)
1.098 0.295 0.836 0.597–1.169
AAU (any) 35.266 <0.001 0.154 0.083–0.286
IBD (Crohn’s
disease or
ulcerative colitis)
13.853 <0.001 0.296 0.156–0.562
AAU, acute anterior uveitis; axSpA, axial spondyloarthritis; BASDAI,
Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath
Ankylosing Spondylitis Functional Index; IBD, inflammatory bowel
disease; TNFi, tumour necrosis factor-inhibitor.
Spondyloarthritis
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and smoking was evident in both unadjusted and adjusted
models. However, smoking is considered an established
risk factor for AAU28 and its negative association with
AAU in this study should be interpreted with caution.
First, there are differences between studies regarding
comparison groups; all participants of the current study
had confirmed axSpA, in contrast to studies reporting the
associations with different background diseases or even in
the general population.29 Furthermore, while a similar
inverse association between smoking and AAU was
reported in a recent study using the same registry
data,30 subsequent analysis showed that smoking does
not protect patients with axSpA from uveitis attacks.31
Other studies have also demonstrated this negative asso-
ciation between smoking and uveitis: Jones et al, in a study
of around 1000 patients from Scotland, found that ex-
smokers weremore than twice as likely to have a history of
uveitis compared to current smokers.32 Further investiga-
tion using different populations and methodology
designed specifically to examine the relationship between
AAU and smoking in patients with axSpA is required.33
The presence of EAMs in general did not increase the
likelihood of participants being started on a biologic in
this cohort. This presumably reflects the focus on axSpA
disease activity threshold scores in the axSpA treatment
recommendations,2 4 5 such that the decision to prescribe
biologics in axSpA is based largely on axSpA disease
activity assessment by the rheumatology team, rather
than the overall disease burden. IBD and psoriasis often
require biological therapy in their own right (prescribed
by gastroenterologists or dermatologists), but these
patients are unlikely to be captured in this cohort which
only recruited participants from rheumatology clinics, so
the cohort may have missed those with the most severe
IBD, psoriasis or AAU. As EAMs contribute to the disease
burden in axSpA,2 3 it could be argued that a composite
axSpA disease burden score incorporating EAMs, and
functional measures, might be more representative of
the true axSpA disease burden than the current disease
activity scores (BASDAI and ASDAS), which are domi-
nated by subjective pain and fatigue scores. This
approach may be worthy of further study and help
address the value of combined clinics with other special-
ties. Although we believe that rheumatologists usually
take the full burden of disease into consideration, in
many countries, patient-reported outcomes are used as
a reimbursement criterion.
The presence of EAMs, specifically IBD and AAU, did
however influence the choice of TNFi. It is clear that
rheumatologists are taking the lack of evidence (or even
paradox effect) for etanercept in IBD, and to a lesser
extent also AAU34 into consideration when choosing
a specific TNFi for patients with axSpA. The presence of
psoriasis did not appear to influence the choice of TNFi
in this cohort, which was largely recruited prior to the
introduction and wide-spread use of IL-17A inhibitors.
EAMs are likely to have a major impact on the choice of
TNFi versus IL-17A inhibitors in axSpA as there remains
concern about the latter exacerbating IBD.35 36 In con-
trast, IL-17A inhibitors have been shown in head-to-head
studies to have greater efficacy in psoriasis.37 38 It should
be noted that to-date no head-to-head studies of biologics
have been reported in axSpA, so data from observational
studies will be required to help address these questions. It
is unfortunate that, due to the funding of the BSRBR-AS,
for the majority of the data collection period only certain
TNFi agents were eligible for inclusion. For example, the
study therefore has no participants commencing inflixi-
mab as first-choice TNFi. However, in the current analy-
sis, all monoclonal antibodies were analysed as a group,
and we believe it is unlikely that the additional of patients
on infliximab (had that data been available) would have
altered the conclusions in the comparison between
monoclonal antibodies versus the soluble fusion protein
etanercept. Beyond the impact of EAMs on choice of
biologic in axSpA assessed in this study, longitudinal real-
world studies will be required to assess the impact of
EAMs on TNFi retention, which will help inform treat-
ment decisions and recommendations for the use of bio-
logics in axSpA. Lindstrom et al reported that AAU and
psoriasis but not IBD affect retention of first TNFi in
a Swedish cohort of patients with AS39; however, more
data are needed.
This ‘real-world’ cohort provides valuable information
on the occurrence of EAMs in axSpA and their influence
on TNFi prescribing patterns. The main strength of the
study is the large sample size and the fact that patients
have been recruited from 83 specialist and non-specialist
centres throughout the UK. To our knowledge, this is
the first study designed to address this subject. It is
reassuring to note that clinicians are prescribing in line
with licenced and international recommendations.
Future analysis will determine whether EAMs influence
TNF efficacy and survival and whether or not individual
TNFi protect patients from incident or flares of existing
EAMs.
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